Pricing Log in Create free account
Saturday 17 October 2026 Export LLY’s income statement to Excel — free account

Eli Lilly and Company

LLY Healthcare Drug Manufacturers General

Eli Lilly and Company’s revenue for fiscal 2025 (year ended December 2025) was $65.2 billion, up 44.7% from fiscal 2024. In the quarter to June 2026, revenue grew 47.7%, EPS grew 26.2%, free cash flow grew 458.1% and total debt rose 37.6%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for twenty-five consecutive years, revenue growth for five.

1,257.03 5.42 +0.43%
Market cap
$1.18T
P/E
42.2×
Fwd P/E
33.1×
Dividend yield
0.53%
F-score
7/9
Altman Z
8.61
Beneish M
−1.91
Dividend safety
86/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Eli Lilly and Company (LLY) Price to free cash flow

Alert me on Price to free cash flow

As of 16 October 2026, Eli Lilly and Company (LLY) trades at a price to free cash flow of 55.0×. Over the past ten years it has ranged from 15.8× (February 2018) to 518× (June 2024); the current reading is higher than 72% of that period. That is above the Drug Manufacturers General industry median of 16.5× and above the Healthcare sector median of 20.2×.

Price to free cash flow, daily

Embed this chart

Annual newest first

Period Price to free cash flow Change
FY2025 86.3× (26.00%)
FY2024 117× (46.13%)
FY2023 217× 281.38%
FY2022 56.8× 46.53%
FY2021 38.7× 39.60%
FY2020 27.8× (4.46%)
FY2019 29.0× 15.38%
FY2018 25.2× 39.85%
FY2017 18.0× (2.02%)
FY2016 18.4× (50.70%)

Quarterly newest first

Period Price to free cash flow Change
Jun 2026 52.5× (10.52%)
Mar 2026 58.7× (32.03%)
Dec 2025 86.3× 44.69%
Sep 2025 59.6× (39.61%)
42 more quarters

Against its own ten years

Low 15.8× High 518×
Ten-year median 33.9×
Current reading's percentile 72

Price to free cash flow against peers

Company Price to free cash flow
GILD Gilead Sciences, Inc. compare 15.0×
PFE Pfizer Inc. compare 16.5×
NVS Novartis AG compare 18.9×
MRK Merck & Co., Inc. compare 22.4×
AMGN Amgen Inc. compare 24.0×
JNJ Johnson & Johnson compare 27.1×
ABBV AbbVie Inc. compare 27.7×
AZN AstraZeneca PLC compare 40.9×
LLY Eli Lilly and Company 55.0×
Drug Manufacturers General industry median 16.5×
Healthcare sector median 20.2×
Market median 14.2×

What Price to free cash flow is

Price to Free Cash Flow Ratio shows how much investors pay for each dollar of cash a company generates after its capital spending.

Stock Price ÷ ((Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM)) ÷ (Shares (Basic, Weighted) (latest quarter)))

The full definition of Price to free cash flow →

More on LLY